Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients

Circulation: Cardiovascular Imaging

Volumn 4, Issue 2, 2011, Pages 87-93

  Gerson, Myron C ^a   Caldwell, James H ^b   Ananthasubramaniam, Karthik ^c   Clements, Ian P ^d   Henzlova, Milena J ^e   Amanullah, Aman ^f   Jacobson, Arnold F ^g  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN MEDICAL CENTER   (United States)

^g GE HEALTHCARE   (United States)

Author keywords

Diabetes mellitus; Heart failure; Nervous system, sympathetic; Prognosis; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BRAIN NATRIURETIC PEPTIDE; NORADRENALIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LATE HEART TO MEDIASTINUM RATIO; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; SCINTISCANNING; SYMPATHETIC INNERVATION;

3-IODOBENZYLGUANIDINE; AGED; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 80051891806     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.110.954784     Document Type: Article

References (26)

1. Institute for Clinical Systems Improvement. Heart Failure in Adults. Bloomington, MN: Institute for Clinical Systems Improvement; 2007: 119.
2. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, Torp-Pedersen C, DIAMOND Study Group. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771-777. (Pubitemid 38296474)
3. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1084;311:819-823.
4. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande J-L, Duval A-M, Loisance D, Castaigne A, Syrota A. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40: 917-923. (Pubitemid 29269210)
5. 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29: 1147-1159. (Pubitemid 351844881)
6. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J. Myocardial iodine-123 metaiodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF AdeView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212-2221.
7. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylgua-nidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myo-cardial ischemia. J Am Coll Cardiol. 1995;25:610-618.
8. Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M, Nakazato M, Kurose T, Wakamatsu H. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34-42. (Pubitemid 43192727)
9. Allman KC, Stevens MJ, Wieland DM, Hutchins GD, Wolfe ER Jr, Greene DA, Schwaiger M. Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol. 1993;22:1425-1432. (Pubitemid 23316369)
10. 123I-mIBG scintigra-phy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16:113-121.
11. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons, Inc; 2000:116-128.
12. Lee K-H, Jang H-J, Lee EJ, Choe YS, Choi Y, Lee MG, Lee SH, Kim BT. Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. Am J Cardiol. 2003;92:1458-1461. (Pubitemid 37532573)
13. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, Heethaar RM, Stehouwer CD. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001;24:1793-1798. (Pubitemid 33716484)
14. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol. 1993;22:1433-1437. (Pubitemid 23316370)
15. Di Carli MF, Bianco-Batles D, Landa ME, Kazmers A, Groehn H, Muzik O, Grunbergo G. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999;100:813-819. (Pubitemid 29398878)
16. Stevens MJ, Dayanika F, Raffel DM, Allman KC, Sandford T, Feldman EL, Wieland DW, Corbett J, Schwaiger M. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervations and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol. 1998;31:1575-1584. (Pubitemid 28273301)
17. Canetti M, Akhter MW, Lerman A, Karaalp IS, Zell JA, Singh H, Mehra A, Elkayam U. Evaluation of myocardial blood flow reserve in patients with chronic congestive heart failure due to idiopathic dilated cardiomy-opathy. Am J Cardiol. 2003;92:1246-1249. (Pubitemid 37377848)
18. Kreiner G, Wolzt M, Fasching P, Leitha T, Edlmayer A, Korn A, Waldhaust W, Dudczak R. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervations in patients with IDDM: comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes. 1995;44:543-549.
19. Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M, Mingardi R, Erle G, Fasoli G, Dalla Volta S. Myocardial dysfunction and adrenergic cardiac innervations in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998;31:404-412. (Pubitemid 28153462)
20. Dae MW, O'Connell JW, Botvinick EH, Ahearn T, Yee E, Huberty JP, Mori H, Chin MC, Hattner RS, Herre JM, Munoz L. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 1989; 79:634-644. (Pubitemid 19087715)
21. Tamura K, Utsunomiya K, Nakatani Y, Saika Y, Onishi S, Iwasaka T. Use of iodine-123 metaiodobenzylguanidine scintigraphy to assess cardiac sympathetic denervation and the impact of hypertension in patients with non-insulin- dependent diabetes mellitus. Eur J Nucl Med. 1999;26:1310-1316. (Pubitemid 29467026)
22. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, Unlu M, Estorch M, Banerjee G, Jacobson AF. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535-546.
23. Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail. 2003;9:384-391. (Pubitemid 37351807)
24. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126-133. (Pubitemid 38949906)
25. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Evaluation of cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J. 2007;28:989-995. (Pubitemid 47343912)
26. Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med. 2007;48:1993-2000. (Pubitemid 350232308)